Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acer rubrum pollen is an allergenic extract derived from the pollen of the red maple tree (*Acer rubrum*). [16] This biological product is used for both the diagnosis and treatment of allergies to red maple pollen. [2] For diagnosis, it is administered via percutaneous or intradermal skin tests to identify patient sensitivity. [11] For treatment, it is used in allergen-specific immunotherapy (also known as hyposensitization) administered through subcutaneous injections. [11, 12] The therapy involves gradually increasing doses of the extract to modulate the patient's immune response, inducing tolerance and reducing the allergic symptoms associated with pollen exposure. [12] It is classified as a non-standardized allergenic product and is available as a solution for injection, manufactured by several companies specializing in allergy products. [2, 11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Acer rubrum pollen.